Tonix Pharmaceuticals Holding (TNXP) Operating Income (2023 - 2025)
Historic Operating Income for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Q3 2025 value amounting to -$33.1 million.
- Tonix Pharmaceuticals Holding's Operating Income fell 11259.48% to -$33.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$99.9 million, marking a year-over-year increase of 2942.64%. This contributed to the annual value of -$136.7 million for FY2024, which is 1547.64% down from last year.
- According to the latest figures from Q3 2025, Tonix Pharmaceuticals Holding's Operating Income is -$33.1 million, which was down 11259.48% from -$28.3 million recorded in Q2 2025.
- Tonix Pharmaceuticals Holding's Operating Income's 5-year high stood at -$15.6 million during Q3 2024, with a 5-year trough of -$77.3 million in Q2 2024.
- For the 3-year period, Tonix Pharmaceuticals Holding's Operating Income averaged around -$30.0 million, with its median value being -$27.3 million (2023).
- Over the last 5 years, Tonix Pharmaceuticals Holding's Operating Income had its largest YoY gain of 6340.21% in 2025, and its largest YoY loss of 11259.48% in 2025.
- Tonix Pharmaceuticals Holding's Operating Income (Quarter) stood at -$27.3 million in 2023, then rose by 17.74% to -$22.5 million in 2024, then crashed by 47.1% to -$33.1 million in 2025.
- Its Operating Income was -$33.1 million in Q3 2025, compared to -$28.3 million in Q2 2025 and -$16.1 million in Q1 2025.